OrthoPediatrics Corp.
OrthoPediatrics Corp. (KIDS) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for OrthoPediatrics Corp. (KIDS), covering cash flow, earnings, and balance sheets.
OrthoPediatrics Corp. (KIDS) Income Statement & Financial Overview
Analyze OrthoPediatrics Corp.’s KIDS earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $61.08M | $52.41M | $52.67M | $54.57M |
| Cost of Revenue | $17.06M | $14.15M | $17.10M | $14.51M |
| Gross Profit | $44.02M | $38.26M | $35.56M | $40.06M |
| Gross Profit Ratio | $0.72 | $0.73 | $0.68 | $0.73 |
| R&D Expenses | $2.16M | $2.35M | $2.92M | $2.58M |
| SG&A Expenses | $49.55M | $46.85M | $41.22M | $43.05M |
| Operating Expenses | $51.70M | $49.20M | $49.62M | $45.63M |
| Total Costs & Expenses | $68.77M | $63.35M | $66.72M | $60.14M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.12M | $1.13M | $1.32M | $404000.00 |
| Depreciation & Amortization | $0.00 | $5.05M | $3.99M | $5.28M |
| EBITDA | -$7.69M | -$4.29M | -$1.31M | -$3.45M |
| EBITDA Ratio | -$0.13 | -$0.08 | -$0.02 | -$0.06 |
| Operating Income | -$7.69M | -$10.98M | -$8.57M | -$5.57M |
| Operating Income Ratio | -$0.13 | -$0.21 | -$0.16 | -$0.10 |
| Other Income/Expenses (Net) | $622000.00 | $518000.00 | -$7.84M | -$3.57M |
| Income Before Tax | -$7.06M | -$10.46M | -$16.41M | -$9.14M |
| Income Before Tax Ratio | -$0.12 | -$0.20 | -$0.31 | -$0.17 |
| Income Tax Expense | $49000.00 | $196000.00 | -$340000.00 | -$1.22M |
| Net Income | -$7.11M | -$10.66M | -$16.07M | -$7.92M |
| Net Income Ratio | -$0.12 | -$0.20 | -$0.31 | -$0.15 |
| EPS | -$0.30 | -$0.46 | -$0.69 | -$0.34 |
| Diluted EPS | -$0.30 | -$0.46 | -$0.69 | -$0.34 |
| Weighted Avg Shares Outstanding | $23.35M | $23.23M | $23.17M | $23.17M |
| Weighted Avg Shares Outstanding (Diluted) | $23.35M | $23.23M | $23.17M | $23.17M |
Over the last four quarters, OrthoPediatrics Corp. achieved steady financial progress, growing revenue from $54.57M in Q3 2024 to $61.08M in Q2 2025. Gross profit stayed firm with margins at 72% in Q2 2025 versus 73% in Q3 2024. Operating income totaled -$7.69M in Q2 2025, maintaining a -13% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$7.69M. Net income rose to -$7.11M, with EPS at -$0.30. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan